全球基于 NGS 的 RNA 定序市场规模（按产品/服务、技术、应用、最终用户、地区、范围和预测）

基于NGS的RNA定序市场规模及预测

基于 NGS 的 RNA-Seq 市场规模预计在 2023 年价值 31.7 亿美元，并在 2031 年达到 128.1 亿美元，从 2024 年到 2031 年的复合年增长率为 19.05%。基于NGS的RNA-Seq（基于次世代定序的RNA定序）是一种可以彻底研究和量化样本总RNA含量的技术。基于NGS 的RNA-Seq 将RNA 转换为cDNA 片段库，然后使用高通量定序方法读取这些片段，以发现已知和新的转录物、量化基因表现水平并识别可变剪接事件。诸如发现之类的见解。基于NGS的RNA-Seq有许多应用，包括基础研究和临床诊断。在研究中，它们用于研究不同条件下的基因表现模式，以瞭解疾病的分子原因并确定未来的治疗目标。

此外，它们还可用于传染病研究，用于检测和表征病原体，并可用于农业中农作物和牲畜的基因改良。

全球基于 NGS 的 RNA 定序市场动态

影响基于 NGS 的 RNA 定序市场的关键市场动态

主要市场驱动因子

技术进步：

次世代定序 (NGS) 技术的不断改进，提高了 RNA 定序的速度和准确性，同时显着降低了其成本。这使得基于NGS的RNA-Seq更易于获取并更适合研究和临床诊断，从而促进市场成长。

个人化医疗需求不断成长：

基于NGS的RNA-Seq对于瞭解疾病的遗传基础至关重要，这对于个人化治疗的开发必不可少。对个人化治疗方法的日益重视推动了临床实践对 RNA-Seq 的需求。

增加基因研究：

基因研究正在兴起，特别是在癌症、神经病学和传染病领域。基于NGS的RNA-Seq提供了对基因表现、调控和剪接的详细见解，从而促进了这些研究领域的进步，并推动了市场的发展。

扩大在药物发现与开发的应用：

基于NGS的RNA-Seq越来越多地用于药物研究和开发，以寻找新的治疗靶点并在基因组层面上更好地了解药物反应。此应用是RNA-Seq市场的主要驱动力。

主要问题：

资料管理要求高：

基于NGS的RNA-Seq会产生大量数据，对数据储存、管理和分析带来重大障碍。需要先进的生物资讯工具和知识来处理和理解数据，这对小型实验室和研究机构来说是一个重大障碍，限制了市场的成长。

样品製备的复杂性：

基于NGS的RNA-Seq的样本製备复杂且容易出错，进而影响结果的准确性。这种复杂性需要训练有素的工作人员，并增加了 RNA 定序工作的时间和成本，从而减少了市场需求。

成本限制：

即使 NGS 技术的成本正在下降，NGS 设备的初始成本以及试剂、维护和资料处理的持续成本对某些组织来说仍然是难以承受的。这阻碍了 RNA-Seq 在资源受限环境中的广泛应用。

主要趋势：

整合人工智慧与机器学习：

在基于 NGS 的 RNA-Seq 中使用 AI 和 ML 技术正变得越来越流行，以有效管理和分析大量数据。这些工具有助于识别基因表现数据中的复杂模式，进而改善研究成果和诊断准确性。

单细胞 RNA 定序（scRNA-Seq）的发展：

单细胞 RNA 定序的需求正在迅速增长，因为它能够更精确地研究样本中细胞的突变和功能。这一趋势从根本上改变了我们对单细胞层面的生物学和疾病的理解。

多路復用与高通量技术：

多重和高通量定序技术使得同时分析多个样本和基因成为可能。这将提高效率并降低每个样本的成本，使得RNA-Seq更容易获得并广泛应用于研究和临床诊断，有助于扩大市场。

扩展到临床诊断：

在临床诊断中使用基于 NGS 的 RNA-Seq 在基因组层面上发现和瞭解疾病的趋势日益增长。这包括癌症诊断、传染病和基因异常的应用，为更个人化和有效的治疗铺平了道路。

目录

第 1 章 全球基于 NGS 的 RNA 定序市场简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章 全球基于 NGS 的 RNA-Seq 市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析
• 监理框架

第 5 章。

• 概述
• 样品製备产品 定序平台和耗材
• 定序服务
• 资料分析、储存与管理

第 6 章 全球基于 NGS 的 RNA 定序市场（以最终用户划分）

• 概述
• 研究和学术机构
• 医院和诊所
• 製药和生技公司
• 其他

第 7 章 全球基于 NGS 的 RNA 定序市场（按应用）

• 概述
• 表达谱分析
• 小RNA定序 从头转录组组装
• 变异调用与转录组表观遗传学

第 8 章。

• 概述 边合成边定序（SBS）
• 离子半导体定序
• 单分子即时定序 奈米孔定序

第 9 章：全球基于 NGS 的 RNA 定序市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 阿根廷
• 世界其他地区

第 10 章：全球基于 NGS 的 RNA 定序市场：竞争格局

• 概述
• 公司市占率
• 供应商概况
• 主要发展策略

第 11 章 公司简介

• Illumina
• Thermo Fisher Scientific
• Agilent Technologies
• F. Hoffmann-La Roche
• QIAGEN
• PerkinElmer
• Pacific Biosciences of California
• Oxford Nanopore Technologies
• Novogene Co.
• BGI

第 12 章附录

• 相关报告

NGS-based RNA-seq Market Size And Forecast

NGS-based RNA-seq Market size was valued at USD 3.17 Billion in 2023 and is projected to reach USD 12.81 Billion by 2031 , growing at a CAGR of 19.05% from 2024 to 2031. NGS-based RNA-seq (Next-Generation Sequencing-based RNA sequencing) is a technology that enables a thorough investigation and quantification of a sample's total RNA content. NGS-based RNA-seq converts RNA into a library of cDNA fragments that are then read using high-throughput sequencing methods, which can discover known and novel transcripts, quantify gene expression levels, and uncover alternative splicing events, among other findings. NGS-based RNA-seq has many applications, including basic research and clinical diagnostics. In research, it is used to investigate gene expression patterns under various situations, gain a molecular understanding of disease causes, and find prospective treatment targets

Furthermore, it is useful in the research of infectious illnesses by allowing for pathogen detection and characterization, as well as in agriculture for crop and livestock genetic improvement.

Global NGS-based RNA-seq Market Dynamics

The key market dynamics that are shaping the NGS-based RNA-seq Market include:

Key Market Drivers

Technological Advancements:

The constant improvement of Next-Generation Sequencing (NGS) technologies has greatly decreased costs while increasing the speed and accuracy of RNA sequencing. This makes NGS-based RNA-seq more accessible and desirable for research and clinical diagnostics, resulting in increased market growth.

Increased Demand for Personalized Medicine:

NGS-based RNA-seq has become crucial for understanding the genetic basis of diseases, which is required for the development of personalized therapy. The rising emphasis on individualized treatment approaches drives up the need for RNA-seq in clinical settings.

Rise in Genetic Research:

There is an increase in genetic research, particularly in cancer, neurology, and infectious disorders. NGS-based RNA-seq gives detailed insights into gene expression, regulation, and splicing, allowing for advances in these study domains and propelling the market.

Expanding Applications in Drug Discovery and Development:

NGS-based RNA-seq is increasingly being utilized in drug research and development to find new therapeutic targets and better understand drug responses at the genomic level. This application is a major driver of the RNA-seq market.

Key Challenges:

High Data Management Requirements:

NGS-based RNA-seq creates massive volumes of data, which presents substantial hurdles in data storage, management, and analysis. This need for sophisticated bioinformatics tools and knowledge to handle and understand data becomes a significant hurdle for smaller laboratories and research institutes, limiting market growth.

Complexity of Sample Preparation:

Sample preparation for NGS-based RNA-seq is complex and error-prone, affecting the accuracy of results. This complexity demands trained staff and increases the time and expense involved with RNA sequencing initiatives, reducing market demand.

Cost Constraints:

The original cost of NGS equipment and continuing expenses for reagents, maintenance, and data processing, even with NGS technology' declining costs, remain unaffordable for certain organizations. This hinders the widespread deployment of RNA-seq in resource-constrained environments.

Key Trends:

Integration of Artificial Intelligence and Machine Learning:

The use of AI and ML technologies in NGS-based RNA-seq is becoming increasingly popular for efficiently managing and analyzing large amounts of data. These tools help to identify complicated patterns in gene expression data for improving research outcomes and diagnosis accuracy.

Single-Cell RNA Sequencing (scRNA-seq) Growth:

Demand for single-cell RNA sequencing is quickly increasing since it allows for a more precise investigation of cellular variations and functions within a sample. This trend is fundamentally changing our understanding of biology and disease at the single-cell level.

Multiplexing and High-Throughput Technologies:

Multiplexing and high-throughput sequencing technologies have made it possible to analyze many samples or genes at the same time. This increases efficiency and lowers the cost per sample, making RNA-seq more accessible and widely used in research and clinical diagnoses, promoting market expansion.

Expansion into Clinical Diagnostics:

There is an increasing trend of using NGS-based RNA-seq in clinical diagnostics to discover and understand disorders at the genomic level. This includes applications in cancer diagnoses, infectious diseases, and genetic abnormalities, paving the path for more personalized and effective therapies.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global NGS-based RNA-seq Market Regional Analysis

Here is a more detailed regional analysis of the NGS-based RNA-seq Market:

North America:

According to Verified Market Research, North America is estimated to dominate in NGS-based RNA-seq Market over the forecast period. North America, particularly the United States, has a strong research infrastructure, including multiple top universities, research organizations, and biotech companies. This climate promotes innovation and rapid adoption of NGS-based RNA-seq technologies, allowing the region to dominate the market

Significant public and private investment in the healthcare and biotechnology industries in North America enables advanced research, development, and application of NGS-based RNA-seq. This financial support speeds up technical breakthroughs and their implementation in healthcare settings.

Personalized medicine is becoming increasingly popular in North America, to tailor medical treatments to individual genetic profiles. NGS-based RNA-seq is critical for understanding genetic variants, thereby, driving its use in both research and clinical diagnostics throughout the region.

Furthermore, the regulatory climate in North America, particularly in the United States, fosters the development and application of NGS-based technologies, thanks to the FDA's proactive approach to genomic and precision medicine. This supporting policy framework shortens the path to market for innovative RNA-seq applications and developments.

Asia Pacific:

Asia Pacific is estimated to grow at the highest CAGR within the NGS-based RNA-seq Market during the forecast period. The region's healthcare sector is expanding rapidly, supported by increased investment and government measures to improve healthcare infrastructure. This expansion encourages the use of modern technologies such as NGS-based RNA-seq in diagnosis and research.

Precision medicine is becoming increasingly important in Asia Pacific countries, to provide patient-specific medicines based on genetic information. As a result of its importance in studying genetic variants, NGS-based RNA-seq is becoming increasingly popular.

The region is experiencing an increase in the prevalence of genetic abnormalities and cancer, necessitating the use of modern diagnostic technologies. NGS-based RNA-seq provides extensive insights into genetic information, allowing for early detection and personalized treatment regimens.

Furthermore, Asia-Pacific is emerging as a hub for biotechnology and pharmaceutical research and development. Governments and commercial organizations are increasing financing for genomics research, accelerating the expansion of NGS-based RNA-seq by providing critical resources for innovation and application in this field.

Europe:

Europe has a rich legacy of international collaborative research, which is encouraged by EU financing programs such as Horizon Europe. These efforts promote the use of NGS-based RNA-seq technologies in a variety of sectors, accelerating growth by pooling resources and expertise.

European countries are investing more in precision medicine, with national and regional initiatives aimed at incorporating genomic data into healthcare. NGS-based RNA-seq is critical for these activities, resulting in increased application in both research and clinical diagnoses.

The most recent genomics technology advancements are being quickly adopted by the European market. This includes NGS-based RNA-seq, which is growing and becoming more accessible across the region because of advances in sequencing efficiency, data processing, and cost reductions, driving market adoption.

Furthermore, the biotech and pharmaceutical industries in Europe are expanding rapidly, with an emphasis on medication discovery and development using genomic data. NGS-based RNA-seq is critical for discovering new therapeutic targets and understanding disease mechanisms, driving its development in these industries.

Global NGS-based RNA-seq Market: Segmentation Analysis

The NGS-based RNA-seq Market is Segmented based on Product & Service, Technology, Application, End-user, And Geography.

NGS-based RNA-seq Market, By Product & Service

• Sample Preparation Products
• Sequencing Platforms and Consumables
• Sequencing Services
• Data Analysis, Storage and Management

Based on Product & Service, the market is segmented into Sample Preparation Products, Sequencing Platforms and Consumables, Sequencing Services, and Data Analysis, Storage & Management. The sequencing platforms and consumables segment is estimated to dominate the NGS-based RNA-seq Market due to the critical function these products play throughout the sequencing process. Sequencing platforms and consumables are critical components of RNA sequencing because they have a direct impact on the efficiency, accuracy, and throughput of the sequencing procedures. The high costs of these platforms, along with the continuous requirement for consumables, ensure that this category receives a sizable share of market income.

NGS-based RNA-seq Market, By Technology

• Sequencing by Synthesis (SBS)
• Ion Semiconductor Sequencing
• Single-molecule Real-time Sequencing
• Nanopore Sequencing

Based on Technology, the market is segmented into Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, and Nanopore Sequencing. The sequencing by synthesis (SBS) segment is estimated to grow at the highest CAGR in the NGS-based RNA-seq Market due to its widespread use in academic research and clinical diagnostics due to its high throughput, precision, and cost-effectiveness when compared with other sequencing methods. SBS, as demonstrated by Illumina's sequencing platforms, has established the gold standard in NGS because it delivers a consistent balance of read length and sequencing depth, making it ideal for a wide range of applications, including transcriptome profiling and whole-genome sequencing.

NGS-based RNA-seq Market, By Application

• Expression Profiling Analysis
• Small RNA Sequencing
• De Novo Transcriptome Assembly
• Variant Calling and Transcriptome Epigenetics

Based on Application, the market is segmented into Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, and Variant Calling & Transcriptome Epigenetics. The expression profiling analysis segment is estimated to exhibit the highest growth within the market over the forecast period due to the crucial role that expression profiling plays in understanding gene function, regulation, and the genetic basis of illness. Expression profiling analysis using NGS-based RNA-seq offers unprecedented depth and breadth in assessing the expression levels of thousands of genes at the same time, providing insights into the molecular signatures of distinct cells and tissues under varied settings.

NGS-based RNA-seq Market, By End-User

• Research and Academia
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Others

Based on End-User, the market is segmented into Research and Academia, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Others. The research and academia segment is estimated to grow at the highest CAGR in the market over the forecast period owing to the widespread use of NGS-based RNA sequencing in basic and applied research to get an unprecedented understanding of genomic expressions, variants, and functions. Globally, academic and research organizations make significant investments in genomic research, using RNA-seq technology to investigate difficult biological problems, disease processes, and evolutionary studies.

Key Players

• The "Global NGS-based RNA-seq Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Illumina, Thermo Fisher Scientific, Agilent Technologies, F. Hoffmann-La Roche, QIAGEN, PerkinElmer, Pacific Biosciences of California, Oxford Nanopore Technologies, Novogene Co., BGI, Macrogen, GENEWIZ, Eurofins Genomics, Twist Bioscience Corporation, MGI Tech Co., Paragon Genomics, NanoString Technologies, Lexogen, and Singular Genomics Systems.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• NGS-based RNA-seq Market Recent Developments
• In February 2024, Illumina announced its new "NovaSeq X Plus" sequencing equipment, which promises quicker run times and increased throughput for single-cell RNA-seq applications. This technology is intended to be especially useful for researchers investigating intricate biological processes at the cellular level.
• In February 2024, BGI and Berry Genomics announced a collaboration to create an AI-powered platform for analyzing RNA-seq data. This platform is intended to increase the accuracy and efficiency of RNA-seq data analysis, resulting in faster and more precise diagnoses and treatment strategies.
• In February 2024, NanoString Technologies received FDA approval for its GeoMx NGS Targeted Assay, a next-generation sequencing (NGS) solution for targeted gene expression analysis. This approval opens up new avenues for applying NGS technology in clinical settings.
• In February 2024, 10x Genomics and Sema4 announced a collaboration to develop and commercialize spatial transcriptomics technologies. This cooperation seeks to combine 10x Genomics' spatial biology knowledge with Sema4's artificial intelligence and machine learning skills, resulting in advanced solutions for analyzing the spatial distribution of RNA in tissues.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NGS-BASED RNA-SEQ MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL NGS-BASED RNA-SEQ MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL NGS-BASED RNA-SEQ MARKET, BY PRODUCT & SERVICE

• 5.1 Overview
• 5.2 Sample Preparation Products
• 5.3 Sequencing Platforms and Consumables
• 5.4 Sequencing Services
• 5.5 Data Analysis, Storage and Management

6 GLOBAL NGS-BASED RNA-SEQ MARKET, BY END-USER

• 6.1 Overview
• 6.2 Research and Academia
• 6.3 Hospitals and Clinics
• 6.4 Pharmaceutical and Biotechnology Companies
• 6.5 Others

7 GLOBAL NGS-BASED RNA-SEQ MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Expression Profiling Analysis
• 7.3 Small RNA Sequencing
• 7.4 De Novo Transcriptome Assembly
• 7.5 Variant Calling and Transcriptome Epigenetics

8 GLOBAL NGS-BASED RNA-SEQ MARKET, BY TECHNOLOGY

• 8.1 Overview
• 8.2 Sequencing by Synthesis (SBS)
• 8.3 Ion Semiconductor Sequencing
• 8.4 Single-molecule Real-time Sequencing
• 8.5 Nanopore Sequencing

9 GLOBAL NGS-BASED RNA-SEQ MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Argentina
• 9.6 Rest of the World

10 GLOBAL NGS-BASED RNA-SEQ MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Share
• 10.3 Vendor Landscape
• 10.4 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Illumina
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Thermo Fisher Scientific
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Agilent Technologies
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 F. Hoffmann-La Roche
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 QIAGEN
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 PerkinElmer
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Pacific Biosciences of California
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Oxford Nanopore Technologies
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Novogene Co.
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 BGI
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 Appendix

• 12.1 Related Reports